The Paterson Institute for Cancer Research is a leading cancer research institute within The University of Manchester, core funded by Cancer Research UK, the largest independent cancer research organisation in the world.
Research spans the whole spectrum of cancer research, from programmes investigating the molecular and cellular basis of cancer, to those focussed on translational research and the development of therapeutics.
The Flk1-cre Mediated Deletion of ETV2 Defines Its Narrow Temporal Requirement During Embryonic Hematopoietic Development.
Wareing S, Mazan A, Pearson S, Göttgens B, Lacaud G, Kouskoff V. Stem Cells. 2012 May 8. [Epub ahead of print].
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Cummings J, Zweifel M, Smith N, Ross P, Peters J, Rustin G, Price P, Middleton MR, Ward T, Dive C. Br J Cancer. 2012 Apr 26. [Epub ahead of print].
Novel Steroid Inhibitors of Glucose 6-Phosphate Dehydrogenase.
Hamilton NM, Dawson M, Fairweather EE, Hamilton NS, Hitchin JR, James DI, Jones SD, Jordan AM, Lyons AJ, Small HF, Thomson GJ, Waddell ID, Ogilvie DJ. J Med Chem. 2012 Apr 27. [Epub ahead of print].